Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing therapies that target genetic drivers of cancer. Co.'s main drug candidate, repotrectinib, is being evaluated for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and patients with NTRK+ advanced solid tumors. Elzovantinib, Co.'s MET/SRC/CSF1R inhibitor, is being evaluated in its ongoing Phase 1 SHIELD-1 clinical trial, in patients with advanced solid tumors harboring genetic alterations in MET. Co.'s clinical trial of its RET inhibitor, TPX-0046 in patients with advanced solid tumors is ongoing. Co.'s fourth drug candidate, TPX-0131, is an ALK inhibitor. The TPTX average annual return since 2019 is shown above.
The Average Annual Return on the TPTX average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TPTX average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TPTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|